<DOC>
	<DOC>NCT00180882</DOC>
	<brief_summary>To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.</brief_summary>
	<brief_title>LMBA02 Protocol for Patients With a Burkitt Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age : 18 years or older Histologically or cytologically proven Burkitt lymphoma according to the WHO classification WHO performance &lt; 3 Informed consent Known HIV positive infection Positive serology for HCV and HBV (except after vaccination) Patients previously treated for lymphoma cardiac disease that contradict anthracycline chemotherapy Psychological or psychiatric condition who contradict steroids therapy Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L) Cirrhosis or severe hepatic failure unrelated to the lymphoma Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule Primary organ transplant or other immunosuppressive conditions Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>